Ovarian Cancer Global Clinical Trials Review, Q4, 2010

Date: November 1, 2010
Pages: 70
Price:
US$ 1,000.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O8823031DD2EN
Leaflet:

Download PDF Leaflet

Ovarian Cancer Global Clinical Trials Review, Q4, 2010
Ovarian Cancer Global Clinical Trials Review, Q4, 2010

Summary

GlobalData's clinical trial report, “Ovarian Cancer Global Clinical Trials Review, Q4, 2010” provides data on the Ovarian Cancer clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Ovarian Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial development throughout the world, focusing on the status of participation by the developing nations. It offers coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides information pertaining to the number of trials for the key drugs for treating Ovarian Cancer.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope
  • Data on the number of clinical trials conducted in North America, South And Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status and trial success rate
  • Review of key discontinued trials (suspended, withdrawn and terminated)
  • Overview of the enrollment pattern by phase for the past decade
  • Number of clinical trials segmented by key drugs
  • Clinical trial overview of top 20 companies, which include Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, and so on.
  • Clinical trial overview of top 20 Universities / Institutes / Hospitals including National Cancer Institute, Cancer Research UK, Cancer Research Institute , and others

Reasons to buy
  • Understand the dynamics of a particular indication as a whole
  • Examine the performance of the trials in terms of their status, recruitment, success rates and others
  • Obtain discontinued trial information for trials across the globe
  • Understand the commercial landscape of the major Universities / Institutes / Hospitals or Companies
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Ovarian Cancer Overview
2.2 Report Guidance

3 CLINICAL TRIALS BY REGION

3.1 Clinical Trials by Country
  3.1.1 Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  3.1.2 Top Five Countries Contributing to Clinical Trials in Europe
  3.1.3 Top Countries Contributing to Clinical Trials in North America
  3.1.4 Top Countries Contributing to Clinical Trials in Middle East and Africa.
  3.1.5 Top Countries Contributing to Clinical Trials in Central and South America
3.2 Clinical Trials by BRIC Countries

4 CLINICAL TRIALS BY PHASE

4.1 In Progress Trials by Phase

5 CLINICAL TRIALS BY TRIAL STATUS

6 UNACCOMPLISHED TRIALS OF OVARIAN CANCER

7 SUBJECTS RECRUITED OVER A PERIOD OF TIME

8 PROMINENT SPONSORS

8.1 Top Companies Participating in Ovarian cancer Therapeutics Clinical Trials

9 PROMINENT DRUG COMPARISON

10 CLINICAL TRIAL PROFILES

10.1 Clinical Trial Overview of Top 10 Companies
  10.1.1 Eli Lilly and Company
  10.1.2 AstraZeneca
  10.1.3 Merck & Co., Inc
  10.1.4 Sanofi-Aventis
  10.1.5 F. Hoffmann-La Roche Ltd.
  10.1.6 GlaxoSmithKline PLC
  10.1.7 Eisai Co., Ltd.
  10.1.8 Johnson & Johnson
  10.1.9 Amgen Inc.
  10.1.10 Takeda Pharmaceutical Company Limited
10.2 Clinical Trial Overview by Top 10 Universities / Institutes / Hospitals
  10.2.1 National Cancer Center (NCI)
  10.2.2 Memorial Sloan Kettering Center
  10.2.3 Gynaecologic Oncology Group
  10.2.4 The University of Texas M.D. Anderson Cancer Center
  10.2.5 Fred Hutchinson Cancer Research Center-Technology Transfer
  10.2.6 European Organization for Research and Treatment of Cancer
  10.2.7 AGO Cancer Study Group
  10.2.8 Cancer Research UK
  10.2.9 Dana-Farber Cancer Institute
  10.2.10 Masonic Cancer Center

11 APPENDIX

11.1 Abbreviations
11.2 Definitions
11.3 Research Methodology
11.4 Secondary Research
11.5 About GlobalData
11.6 Contact Us
11.7 Disclaimer
11.8 Source 70

LIST OF TABLES

Table 1: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Zone (%), 2010*
Table 2: Ovarian cancer Clinical Trials In Progress by Top Countries, 1982-2010*
Table 3: Ovarian cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2010*
Table 4: Ovarian cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2010*
Table 5: Ovarian cancer Therapeutics Clinical Trials, North America, Top Five Countries, 2010*
Table 6: Ovarian cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2010*
Table 7: Ovarian cancer Therapeutics Clinical Trials, Central and South America, Top Countries, 2010*
Table 8: Ovarian Cancer Therapeutics Clinical Trials, BRIC Countries, 2010*
Table 9: Ovarian cancer Therapeutics Market, Global, Clinical Trials by Phase, 2010*
Table 10: Ovarian cancer Therapeutics Market, Global, Clinical Trials in Progress by Phase, 2010*
Table 11: Ovarian cancer Therapeutics Market, Global, Clinical Trials by Trial Status, 2010*
Table 12: Ovarian cancer Therapeutics Market, Global, Suspended Clinical Trials, 2010*
Table 13: Ovarian cancer Therapeutics Market, Global, Terminated Clinical Trials, 2010*
Table 14: Ovarian cancer Therapeutics Market, Global, Withdrawn Clinical Trials, 2010*
Table 15: Ovarian Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2005-2009
Table 16: Ovarian cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2010*
Table 17: Ovarian Cancer Therapeutics Clinical Trials, Global, Enrollment Target Trends by Phase and Year, 2005-2010*
Table 18: Ovarian Cancer Therapeutics Clinical Trials, Global, Clinical Trials in Progress by Prominent Drugs, 2010*
Table 19: Ovarian cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2010*
Table 20: Ovarian cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Astra-Zeneca PLC, 2010*
Table 21: Ovarian cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc. 2010*
Table 22: Ovarian cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi-Aventis, 2010*
Table 23: Ovarian cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2010*
Table 24: Ovarian cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline PLC, 2010*
Table 25: Ovarian cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eisai Co., Ltd., 2010*
Table 26: Ovarian cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson & Johnson, 2010*
Table 27: Ovarian cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2010*
Table 28: Ovarian cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2010*
Table 29: Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Center, 2010*
Table 30: Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2010*
Table 31: Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Gynaecologic Oncology Group, 2010*
Table 32: Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2010*
Table 33: Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center-Technology Transfer, 2010*
Table 34: Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2010*
Table 35: Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AGO Ovarian Cancer Study Group, 2010*
Table 36: Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Cancer Research UK,, 2010*
Table 37: Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Dana-Farber Cancer Institute, 2010*
Table 38: Ovarian Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Masonic Cancer Center, 2010* 66

LIST OF FIGURES

Figure 1: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Zone (%), 2010*
Figure 2: Ovarian cancer Therapeutics Market, Global, Clinical Trials by Top Countries, 2010*
Figure 3: Ovarian cancer Therapeutics Market, Global, Clinical Trials in Progress by Top Countries, 2010*
Figure 4: Ovarian cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2010*
Figure 5: Ovarian cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2010*
Figure 6: Ovarian cancer Therapeutics Clinical Trials, North America, Top Five Countries (%), 2010*
Figure 7: Ovarian cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2010*
Figure 8: Ovarian cancer Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2010*
Figure 9: Ovarian cancer Therapeutics Clinical Trials, BRIC Countries (%), 2010*
Figure 10: Ovarian cancer Therapeutics Market, Global, Clinical Trials by Phase (%), 2010*
Figure 11: Ovarian cancer Therapeutics Market, Global, Clinical Trials in Progress by Phase, 2010*
Figure 12: Ovarian cancer Therapeutics Market, Global, Clinical Trials by Trial Status, 2010*
Figure 13: Ovarian Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2005-2009
Figure 14: Ovarian cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2010*
Figure 15: Ovarian cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2010*
Figure 16: Ovarian Cancer Clinical Trials by Prominent Drugs, 1982-2010*
Figure 17: GlobalData Methodology 68

Ask Your Question

Ovarian Cancer Global Clinical Trials Review, Q4, 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: